Sadoff, Jerald, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne M. de Groot, Jeroen Stoop, et al. “Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine.” New England Journal of Medicine 0, no. 0 (January 13, 2021): null. https://doi.org/10.1056/NEJMoa2034201.
What is an adenovirus vector vaccine?
An adenovirus vector vaccine, or viral vector vaccine uses a modified, harmless virus to deliver information to our cells. This harmless virus carries a gene to our cells that encodes information on how to generate an antibody. The COVID-19 adenovirus vector vaccine contains a virus with a gene telling our cells how to make a marker for SARS-CoV-2 spike protein. The antigen stimulates the body to produce antibodies and launch an immune response. When the body is now armed with antibodies, it will be ready to protect you if you are ever infected with the real SARS-CoV-2 virus.
How successful is the adenovirus vector vaccine?
When researchers tested patients for the presence of antibodies against the virus, they found working antibodies in 90% or more of all participants 29 days after the first vaccine dose. 100% of the participants had antibodies after 57 days. After this time, there was also an increase in the level of antibodies within individuals. Generating antibodies is extremely important because it prepares the immune system to fight the virus if it ever infects individuals.
Should I get the adenovirus vector vaccine if it is offered to me?
You should get the first vaccine that is offered to you. The Moderna, Pfizer, and Johnson & Johnson vaccine will all protect against severe cases of COVID-19 and death. It is important that the population achieves immunity against the virus, and to do that everyone should get vaccinated. The faster we get vaccinated, the less time the virus has time to spread and mutate.